Efficacy and Tolerability of Antidepressants in the Treatment of Behavioral and Psychological Symptoms of Dementia,A Literature Review of Evidence

Abstract

The objective of this review is to summarize the current data on the use of antidepressants in the treatment of behavioral and psychological symptoms of dementia (BPSD) and to determine whether these medications can be recommended for routine clinical use. A literature search of six major databases (PubMed, Medline, PsychINFO, Scopus, Web of Science and Cochrane collaboration) trials, 8 using a selective serotonin reuptake inhibitor (SSRI) compound and 3 using trazodone showed benefit in the treatment of BPSD. The antidepressant drug was well tolerated in at least 14 of the 19 trials with information about tolerability in one trial not provided in the study (paroxetine or placebo for FTD). This review indicates that antidepressants can be an effective in the treatment of BPSD and are generally well tolerated in elderly demented patients.

Keywords

dementia behavioral and psychological symptoms of dementia antidepressants selective serotonin reuptake inhibitors trazodone

References

Lawlor B. Managing behavioural and psychological symptoms in dementia. Br J Psychiatry. 2002;181:463-465.

Bharucha AJ , Rosen J. , Mulsant BH , Pollock BG Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002;7(11):797-802.

Lyketsos CG , Steinberg M. , Tschanz JT , Norton MC , Steffens DC , Breitner JC Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000;157(5):708-714.

Margallo-Lana M. , Swann A. , O’Brien J. , et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001;16(1):39-44.

Lyketsos CG , Olin J. Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry. 2002;52(3):243-252.

Burns A. , Jacoby R. , Levy R. Psychiatric phenomena in Alzheimer’s disease. I: Disorders of thought content. Br J Psychiatry. 1990;157:72-76; 92-94.

Lanari A. , Amenta F. , Silvestrelli G. , Tomassoni D. , Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev. 2006;127(2):158-165.

Ballard C. , Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010;24(9):729-739.

Nyth AL , Gottfries CG The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry . 1990;157:894-901.

10.

Olafsson K. , Jørgensen S. , Jensen HV , Bille A. , Arup P. , Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992;85(6):453-456.

11.

Auchus AP , Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 1997;9(4):591-593.

12.

Magai C. , Kennedy G. , Cohen CI , Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer’s disease. Am J Geriatr Psychiatry. 2000;8(1):66-74.

13.

Gaber S. , Ronzoli S. , Bruno A. , Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl. 2001;7:159-162.

14.

Lanctôt KL , Herrmann N. , van Reekum R. , Eryavec G. , Naranjo CA Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531-541.

15.

Pollock BG , Mulsant BH , Rosen J. , et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465.

16.

Moretti R. , Torre P. , Antonello RM , Cazzato G. , Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol . 2003;49(1):13-19.

17.

Lyketsos CG , DelCampo L. , Steinberg M. , et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60(7):737-746.

18.

Finkel SI , Mintzer JE , Dysken M. , Krishnan KR , Burt T. , McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry . 2004;19(1):9-18.

19.

Deakin JB , Rahman S. , Nestor PJ , Hodges JR , Sahakian BJ Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172(4):400-408.

20.

Pollock BG , Mulsant BH , Rosen J. , et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia . Am J Geriatr Psychiatry. 2007;15(11):942-952.

21.

Siddique H. , Hynan LS , Weiner MF Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s disease. J Clin Psychiatry. 2009;70(6):915-918.

22.

Weintraub D. , Rosenberg PB , Drye LT , et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010;18(4):332-340.

23.

Culo S. , Mulsant BH , Rosen J. , et al. Treating neuropsychiatric symptoms in dementia with lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord . 2010;24:360-364.

24.

Sultzer DL , Gray KF , Gunay I. , Berisford MA , Mahler ME A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997;5(1):60-69.

25.

Teri L. , Logsdon RG , Peskind E. , et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271-1278.

26.

Sultzer DL , Gray KF , Gunay I. , Wheatley MV , Mahler ME Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc. 2001;49(10):1294-1300.

27.

Lebert F. , Stekke W. , Hasenbroekx C. , Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355-359.

28.

Palmer AM , Stratmann GC , Procter AW , Bowen DM Possible neurotransmitter basis of behavioral changes in Alzheimer’s disease. Ann Neurol. 1988;23(6):616-620.

29.

Mintzer J. , Brawman-Mintzer O. , Mirski DF , et al. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer’s dementia and agitation. Biol Psychiatry. 1998;44(9):918-921.

30.

Zubenko GS Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology. 1992;6(2):77-93.

31.

Pollock BG , Mulsant BH , Sweet R. , et al. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. J Am J Geriatr Psychiatry. 1997;5(1):70-78.

32.

Sparks DL , Markesbery WR Altered serotonergic and cholinergic synaptic markers in Pick’s disease . Arch Neurol. 1991;48(8):796-799.

33.

Swartz JR , Miller BL , Lesser IM , Darby AL Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58(5):212-216.

34.

Sink KM , Holden KF , Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.